Join to access to all OVN content. Join for Free
How to Create a GREAT MSL Team Culture
Chad Fellers team dynamics in medical affairs team-centric culture fostering development recruiting for cultural fit

How to Create a GREAT MSL Team Culture


Share This Article


Summary

In this episode, Chad Fellers joins to discuss the crucial elements of team dynamics and leadership in medical affairs. Chad shares insights into his background, emphasizing the importance of a team-centric culture and how positive intent in communication extends beyond the workplace. The conversation delves into the significance of trust, fostering development, and recruiting for cultural fit to ensure career satisfaction. Chad also reflects on adapting team culture during the pandemic, offering practical strategies. The episode concludes with a nod to the podcast's mission and encouragement for listener engagement.

Chad Fellers, Director, Medical Science Liaisons at Harmony Biosciences discusses how to develop a GREAT MSL team culture.

Chad shares…

πŸ‘‰ His strategy, philosophy, and key ingredients for a great team culture

πŸ‘‰ Why culture is so important and the benefits of a great culture

πŸ‘‰ Why a “sense of ownership” is so important

πŸ‘‰ How the pandemic and the virtual world affected the team culture

πŸ‘‰ His “Lead vs manage” philosophy and how to cater to the individual team member for career satisfaction

Click for Source
Chad Fellers, team dynamics in medical affairs, team-centric culture, fostering development, recruiting for cultural fit

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
OVN Avatar Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH

Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions

Article
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
OVN Avatar Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, GaΓ«lle Guyaderb, Lotfi Boudalib, Nicolas Albin

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Article
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
OVN Avatar Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS

Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review

Article
Transforming oncology: Five frontiers driving progress in cancer care
Partner Avatar iNIZIO

Transforming oncology: Five frontiers driving progress in cancer care

Article
Virtual Oncology MSL Team Increases KOL Engagement by 120%
Partner Avatar iNIZIO

Virtual Oncology MSL Team Increases KOL Engagement by 120%

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Explore OVN